KANUMA

Clinical safety rating: caution

Comprehensive clinical and safety monograph for KANUMA (KANUMA).

How it works

Recombinant human lysosomal acid lipase (LAL) that catalyzes the hydrolysis of cholesteryl esters and triglycerides in lysosomes.

What the body does with it

Metabolism	Degraded into small peptides and amino acids via proteolysis.
Excretion	Primarily cleared via receptor-mediated endocytosis and lysosomal degradation; negligible renal or biliary/fecal elimination of active drug. <1% excreted unchanged in urine.
Half-life	Terminal elimination half-life: approximately 2–5 hours (range 1.5–7.5 hours) in patients with LAL deficiency. Clinical context: half-life supports weekly intravenous dosing.
Protein binding	Approximately 20–30% bound to plasma proteins (including α2-macroglobulin).
Volume of Distribution	Vd: 0.2–0.5 L/kg, indicating distribution primarily within extracellular fluid and plasma.
Bioavailability	Intravenous only; not administered via other routes. Bioavailability is 100% for IV formulation.
Onset of Action	Intravenous: reduction in hepatic fat content and improvement in serum transaminases observed within 4–8 weeks of starting weekly infusions.
Duration of Action	Weekly intravenous administration maintains therapeutic effect; sustained improvement in lipid profiles and liver parameters with continued dosing. Effect wanes if doses missed.

Classification & Brands

Dosing & administration

1 mg/kg intravenously over 4 hours once weekly.

Dosage form	INJECTABLE
Renal impairment	No dose adjustment required for renal impairment; safety and efficacy not established in severe renal impairment.
Liver impairment	No dose adjustment required for hepatic impairment; safety and efficacy not established in severe hepatic impairment.
Pediatric use	Same as adult: 1 mg/kg intravenously over 4 hours once weekly for pediatric patients with body weight ≥6 kg.
Geriatric use	No specific dose adjustment recommended; use with caution due to limited data in elderly patients.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for KANUMA (KANUMA).

Breastfeeding	Unknown if distributed into human milk; M/P ratio not determined. Caution advised; consider developmental benefits and risks of breastfeeding.
Teratogenic Risk	No adequate human data; animal studies show no evidence of fetal harm at doses up to 10 times the human exposure. Risk cannot be ruled out; use only if clearly needed.
Fetal Monitoring	Monitor for hypersensitivity reactions; assess liver function tests, coagulation parameters, and signs of pulmonary hypertension.

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warning.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Known severe hypersensitivity to sebelipase alfa or any excipients"]

Clinical Precautions

Precautions

["Hypersensitivity reactions including anaphylaxis","Risk of severe allergic reactions during infusion","Monitor for signs/symptoms of hypersensitivity"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

KANUMA

Clinical safety rating: caution

Comprehensive clinical and safety monograph for KANUMA (KANUMA).

How it works

Recombinant human lysosomal acid lipase (LAL) that catalyzes the hydrolysis of cholesteryl esters and triglycerides in lysosomes.

What the body does with it

Metabolism	Degraded into small peptides and amino acids via proteolysis.
Excretion	Primarily cleared via receptor-mediated endocytosis and lysosomal degradation; negligible renal or biliary/fecal elimination of active drug. <1% excreted unchanged in urine.
Half-life	Terminal elimination half-life: approximately 2–5 hours (range 1.5–7.5 hours) in patients with LAL deficiency. Clinical context: half-life supports weekly intravenous dosing.
Protein binding	Approximately 20–30% bound to plasma proteins (including α2-macroglobulin).
Volume of Distribution	Vd: 0.2–0.5 L/kg, indicating distribution primarily within extracellular fluid and plasma.
Bioavailability	Intravenous only; not administered via other routes. Bioavailability is 100% for IV formulation.
Onset of Action	Intravenous: reduction in hepatic fat content and improvement in serum transaminases observed within 4–8 weeks of starting weekly infusions.
Duration of Action	Weekly intravenous administration maintains therapeutic effect; sustained improvement in lipid profiles and liver parameters with continued dosing. Effect wanes if doses missed.

Classification & Brands

Dosing & administration

1 mg/kg intravenously over 4 hours once weekly.

Dosage form	INJECTABLE
Renal impairment	No dose adjustment required for renal impairment; safety and efficacy not established in severe renal impairment.
Liver impairment	No dose adjustment required for hepatic impairment; safety and efficacy not established in severe hepatic impairment.
Pediatric use	Same as adult: 1 mg/kg intravenously over 4 hours once weekly for pediatric patients with body weight ≥6 kg.
Geriatric use	No specific dose adjustment recommended; use with caution due to limited data in elderly patients.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for KANUMA (KANUMA).

Breastfeeding	Unknown if distributed into human milk; M/P ratio not determined. Caution advised; consider developmental benefits and risks of breastfeeding.
Teratogenic Risk	No adequate human data; animal studies show no evidence of fetal harm at doses up to 10 times the human exposure. Risk cannot be ruled out; use only if clearly needed.
Fetal Monitoring	Monitor for hypersensitivity reactions; assess liver function tests, coagulation parameters, and signs of pulmonary hypertension.

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warning.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Known severe hypersensitivity to sebelipase alfa or any excipients"]

Clinical Precautions

Precautions

["Hypersensitivity reactions including anaphylaxis","Risk of severe allergic reactions during infusion","Monitor for signs/symptoms of hypersensitivity"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…